Nextcure Inc (NXTC) Stock Price, Quote & News

Company Profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease;...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 399 4900

Website: www.nextcure.com

Address:

9000 Virginia Manor Road, Suite 200, Beltsville, United States

neilyoungsband Oct. 6 at 7:24 PM

$SPRB don't miss out on $NXTC why chase something that's already popped...

0 · Reply

neilyoungsband Oct. 6 at 5:39 PM

$SPRB don't miss the $NXTC rocket that's about to happen.....

0 · Reply

neilyoungsband Oct. 6 at 4:34 PM

$VZ wow looks bloody, but maybe not bloody enough for a nice bounce maybe 2 to 3 days of bleeding before pump back maybe more..... you guys ever see $NXTC ? Price action is getting squirrely maybe take a look .....

0 · Reply

neilyoungsband Oct. 6 at 4:31 PM

$NXTC wow can you believe that 200$ is a fair price for this pos...... never going up that high right????? 200÷12 = 16.666....7 ipo was actually 15 pre split.... I'm not saying it's going to 200 but, if they get their shit together actually that's the fair price, all time high pre split was 109..... x 12 well that's just ridiculous bs pump and dump bio tec..... yay

0 · Reply

neilyoungsband Oct. 6 at 3:52 PM

$NXTC wow have you seen the price action here today? Whoa this thing better slow down lol $AMD

0 · Reply

ENERGYEagle Oct. 5 at 3:07 PM

$NXTC Technology hardware micro-cap. No clear pattern. Illiquid conditions. Avoid.

1 · Reply

Vikingsstrade Oct. 3 at 7:22 PM

$NXTC $HTOO $GORV $MFI Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!

0 · Reply

neilyoungsband Oct. 2 at 3:10 PM

$SRPT anyone ruch enough to help me pump $NXTC ? Th little guys could use a win for once lol yay!

0 · Reply

neilyoungsband Oct. 2 at 1:38 PM

$NXTC someone from the $TSLA crew should save us 😆 🤣 oh pos bio tech

0 · Reply

neilyoungsband Oct. 1 at 6:59 PM

$LLY anyone know about $NXTC ?

0 · Reply

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 7, 2025, 4:05 PM EDT - 2 months ago

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 4:05 PM EDT - 2 months ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Jun 16, 2025, 10:03 AM EDT - 4 months ago

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

Jun 16, 2025, 7:05 AM EDT - 4 months ago

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

May 29, 2025, 4:05 PM EDT - 4 months ago

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

May 1, 2025, 4:05 PM EDT - 5 months ago

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 4, 2025, 7:00 AM EDT - 6 months ago

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

Mar 6, 2025, 4:05 PM EST - 7 months ago

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

Jan 10, 2025, 8:05 AM EST - 9 months ago

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

Dec 10, 2024, 8:05 AM EST - 10 months ago

NextCure Announces Acceptance of IND Application for LNCB74

Nov 26, 2024, 7:00 AM EST - 11 months ago

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

Nov 19, 2024, 8:05 AM EST - 11 months ago

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Nov 7, 2024, 4:05 PM EST - 11 months ago

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 4:05 PM EST - 11 months ago

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 1 year ago

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

Sep 16, 2024, 8:05 AM EDT - 1 year ago

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

Jun 20, 2024, 4:10 PM EDT - 1 year ago

NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

May 30, 2024, 4:05 PM EDT - 1 year ago

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

May 2, 2024, 4:05 PM EDT - 1 year ago

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

Apr 24, 2024, 4:05 PM EDT - 1 year ago

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

Apr 8, 2024, 7:00 AM EDT - 1 year ago

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Apr 4, 2024, 7:05 AM EDT - 1 year ago

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

Apr 2, 2024, 7:00 AM EDT - 1 year ago

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 21, 2024, 8:55 AM EDT - 1 year ago

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Mar 5, 2024, 8:05 AM EST - 1 year ago

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

Jan 18, 2024, 4:05 PM EST - 1 year ago

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Dec 21, 2023, 7:05 AM EST - 1 year ago

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Dec 14, 2023, 6:45 AM EST - 1 year ago

NextCure Provides Year-End Clinical Pipeline Updates

Nov 20, 2023, 7:00 AM EST - 2 years ago

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 15, 2023, 4:05 PM EST - 2 years ago

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

Nov 2, 2023, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Oct 17, 2023, 8:05 AM EDT - 2 years ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

Sep 26, 2023, 4:05 PM EDT - 2 years ago

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Disease

$A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC$

Sep 12, 2023, 8:05 AM EDT - 2 years ago

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

Sep 7, 2023, 4:05 PM EDT - 2 years ago

NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen

Sep 5, 2023, 4:05 PM EDT - 2 years ago

Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease

Aug 31, 2023, 7:00 AM EDT - 2 years ago

NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results

Jun 21, 2023, 4:05 PM EDT - 2 years ago

NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

May 9, 2023, 7:00 AM EDT - 2 years ago

NextCure to Present at the JMP Securities Life Sciences Conference

May 4, 2023, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports First Quarter 2023 Financial Results

Apr 11, 2023, 7:00 AM EDT - 2 years ago

NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference

Mar 2, 2023, 4:05 PM EST - 2 years ago

NextCure Provides Business Update and Reports Full Year 2022 Financial Results

Feb 7, 2023, 7:00 AM EST - 2 years ago

NextCure to Present at SVB Securities Global Biopharma Conference

Nov 22, 2022, 8:00 AM EST - 3 years ago

NextCure to Present at Upcoming Investor Conferences

Nov 15, 2022, 4:30 PM EST - 3 years ago

NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates

Nov 7, 2022, 8:05 AM EST - 3 years ago

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

Nov 3, 2022, 4:15 PM EDT - 3 years ago

NextCure Provides Update and Reports Third Quarter 2022 Financial Results

Nov 3, 2022, 9:15 AM EDT - 3 years ago

NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting

neilyoungsband Oct. 6 at 7:24 PM

$SPRB don't miss out on $NXTC why chase something that's already popped...

0 · Reply

neilyoungsband Oct. 6 at 5:39 PM

$SPRB don't miss the $NXTC rocket that's about to happen.....

0 · Reply

neilyoungsband Oct. 6 at 4:34 PM

0 · Reply

neilyoungsband Oct. 6 at 4:31 PM

0 · Reply

neilyoungsband Oct. 6 at 3:52 PM

$NXTC wow have you seen the price action here today? Whoa this thing better slow down lol $AMD

0 · Reply

ENERGYEagle Oct. 5 at 3:07 PM

$NXTC Technology hardware micro-cap. No clear pattern. Illiquid conditions. Avoid.

1 · Reply

Vikingsstrade Oct. 3 at 7:22 PM

0 · Reply

neilyoungsband Oct. 2 at 3:10 PM

$SRPT anyone ruch enough to help me pump $NXTC ? Th little guys could use a win for once lol yay!

0 · Reply

neilyoungsband Oct. 2 at 1:38 PM

$NXTC someone from the $TSLA crew should save us 😆 🤣 oh pos bio tech

0 · Reply

neilyoungsband Oct. 1 at 6:59 PM

$LLY anyone know about $NXTC ?

0 · Reply

neilyoungsband Sep. 30 at 5:10 PM

$MLTX whatever you do, do not buy $NXTC you'll basically just be throwing your cash down the drain.

0 · Reply

neilyoungsband Sep. 30 at 4:37 PM

$NXTC the worst company ever!

0 · Reply

neilyoungsband Sep. 29 at 8:56 PM

$NXTC 6% after hours get in quick 😆

0 · Reply

neilyoungsband Sep. 29 at 8:50 PM

$NXTC when will management actually step in and help?

0 · Reply

neilyoungsband Sep. 29 at 6:14 PM

$NXTC why do companies like this even publicly trade? They shouldn't be allowed. The sec shouldn't allow this bs to happen. This isn't investing its just robbery.

0 · Reply

neilyoungsband Sep. 29 at 4:50 PM

$NXTC complete garbage 🗑 someone needs to take this out back and shoot it.

0 · Reply

InfinityCove Sep. 29 at 3:20 PM

$NXTC NXXT stepping into revenue heavy infrastructure data center plus microgrid theme gets premium multiples PT 4 conservative PT 6 ambitious

1 · Reply

neilyoungsband Sep. 29 at 3:07 PM

$NXTC if only someone could help.

0 · Reply

neilyoungsband Sep. 29 at 2:48 PM

$NXTC trash 🗑 scam alert public notice do not buy!

0 · Reply

neilyoungsband Sep. 29 at 1:18 PM

$KALA don't worry guys at least you're not all in on $NXTC it could be worse

0 · Reply

neilyoungsband Sep. 29 at 12:46 PM

$MLTX could always lose some more and buy $NXTC 😆 🤣 yay!

0 · Reply

MoonCowBoy Sep. 26 at 9:46 PM

retail running GYRO now! the GYRO Float only 600k could squeeze hard wow $PASG $NXTC $HTOO $GORV ++

0 · Reply

Market Cap	15.63M
Revenue (ttm)	0.00
Net Income (ttm)	-55.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	19,600
Avg Vol	21,342
Day's Range	N/A - N/A
Shares Out	2.68M
Stochastic %K	79%
Beta	1.34
Analysts	Sell
Price Target	$17.50